Physician profile
Anjitha Thomas
NPI 1528397668
$663.94
in general payments reported to CMS, 2019-2025
9 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.44 · 2022: $60.13 · 2023: $50.37 · 2024: $363 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $172.39 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Amneal Pharmaceuticals LLC | $170.53 | 2022-2024 | Unithroid |
| Acella Pharmaceuticals, LLC | $85.92 | 2023-2025 | NP Thyroid 60 |
| Lilly USA, LLC | $80.27 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Ibsa Pharma INC. | $54.57 | 2021-2024 | Tirosint, Tirosint, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.14 | 2025 | Xifaxan |
| Exact Sciences Corporation | $27.42 | 2024 | Cologuard Collection Kit |
| Abbvie INC. | $24.81 | 2022 | |
| Antares Pharma, INC. | $17.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjitha Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.